Home Tags Padcev

Tag: Padcev

ESMO 2024: Scientific Progress in Advanced and Hard-to-Treat Cancer

Peter Hofland -

Potential Withdrawal of Accelerated Approved Therapeutic Agents may harm Cancer Patients

Peter Hofland -

Seattle Genetics Rebrands itself as Seagen

Editorial Team -
Seattle Genetics. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO). In the back of the booth the enfortumab vedotin presentation.

Potential Accelerated Approval Enfortumab Vedotin + Pembrolizumab in Metastatic Urothelial Cancer

Peter Hofland -

Combination Enfortumab Vedotin + Pembrolizumab Granted Breakthrough Therapy in Bladder Cancer

Peter Hofland -

Enfortumab Vedotin + Pembrolizumab Shrink Tumors in the Majority of Bladder...

Peter Hofland -
Doctor discussing treatment options with a patient.

FDA Approves Novel Treatments for Metastatic Urothelial Cancer – But More...

Andrea Maddox-Smith -
Seattle Genetics. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO). In the back of the booth the enfortumab vedotin presentation.

FDA Approves New Drug for Advanced Bladder Cancer

Peter Hofland -

LATEST NEWS